IUPHAR Review - Novel therapeutic targets for schizophrenia treatment: a translational perspective

Pharmacological Research, Journal Year: 2025, Volume and Issue: unknown, P. 107690 - 107690

Published: March 1, 2025

Schizophrenia is a severe and debilitating psychiatric disorder that profoundly impacts cognitive, emotional, social functioning. Despite its devastating personal societal toll, current treatments often provide only partial relief, underscoring the urgent need for innovative therapeutic strategies. This review explores emerging approaches target complex neurobiological underpinnings of schizophrenia, moving beyond traditional dopamine-centric models. Among these, some novel drugs still employ multimodal mechanisms, simultaneously targeting dopaminergic serotonergic systems to enhance efficacy tolerability. Given well-documented excitatory/inhibitory imbalance in significant efforts have been directed toward addressing NMDA receptor hypofunctionality. However, strategies this pathway yet demonstrate consistent clinical efficacy. In contrast, therapies cholinergic system shown greater promise. For instance, xanomeline-trospium combination, which modulates muscarinic receptors, has recently gained approval, other molecules with similar mechanisms are currently under development. Beyond these approaches, being explored pathways, including neuroplasticity, neuroinflammation, mitochondrial dysfunction. These designed as part combinatorial strategy available antipsychotic drugs. progress, challenges remain translating experimental discoveries into effective applications. Future research should prioritize biomarker-driven precision medicine optimize individualized treatment outcomes. By integrating targets, schizophrenia may evolve more comprehensive personalized approach, disorder's full spectrum symptoms improving patient quality life.

Language: Английский

---

Effect of aerobic exercise versus cognitive remediation versus a combination of both on cognition among patients with schizophrenia: A three-arm, randomized controlled study

Psychiatry Research, Journal Year: 2025, Volume and Issue: unknown, P. 116454 - 116454

Published: March 1, 2025

Language: Английский

---

Antipsychotika abseits der Dopamin-D2-Blockade – Xanomelin-Trospium als Hoffnungsträger?

Der Nervenarzt, Journal Year: 2025, Volume and Issue: unknown

Published: April 22, 2025

---